194851-16-6

Basic information

• Product Name: 7-BROMO-1H-QUINAZOLIN-4-ONE
• Synonyms: 7-BroMoquinazolin-4-one;7-BroMo-3,4-dihydroquinaz...;7-Bromo-4-quinazolone;7-BroMoquinazolin-4(1H)-one;7-BroMo-3,4-dihydroquinazolin-4-one, 95+%;7-Bromo-3H-quinazolin-4-one;4(1H)-Quinazolinone, 7-bromo-;7-BROMO-1H-QUINAZOLIN-4-ONE
• CAS NO: 194851-16-6
• Molecular Formula: C₈H₅BrN₂O
• Molecular Weight: 225.04
• Product Categories: Halides;CHIRAL CHEMICALS;Fused Ring Systems
• Mol File: 194851-16-6.mol
• Article Data: 33

Chemical Properties

• Boiling Point: 428.784 °C at 760 mmHg
• Flash Point: 213.121 °C
• Appearance: /
• Density: 1.822 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.721
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.36±0.20(Predicted)
• CAS DataBase Reference: 7-BROMO-1H-QUINAZOLIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BROMO-1H-QUINAZOLIN-4-ONE(194851-16-6)
• EPA Substance Registry System: 7-BROMO-1H-QUINAZOLIN-4-ONE(194851-16-6)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 194851-16-6(Hazardous Substances Data)

Usage

General Description

7-BROMO-1H-QUINAZOLIN-4-ONE is a chemical compound with the molecular formula C8H5BrN2O. It is a heterocyclic organic compound belonging to the quinazolinone family. 7-BROMO-1H-QUINAZOLIN-4-ONE has a bromine atom attached to the quinazolinone ring, and it is commonly used as a building block in organic synthesis and medicinal chemistry. It has potential pharmacological applications and has been studied for its potential as an antitumor agent and in other therapeutic areas. Its structure and reactivity make it useful for the development of pharmaceuticals and agrochemicals, as well as in research and development of new chemical compounds.

InChI:InChI=1/C8H5BrN2O/c9-5-1-2-6-7(3-5)10-4-11-8(6)12/h1-4H,(H,10,11,12)

Upstream product

• 20776-50-5 2-amino-4-bromobenzoic acid 
• 463-52-5 formamidine 
• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 122-51-0 orthoformic acid triethyl ester 
• 77287-34-4 formamide 
• 1427534-38-0 methyl (E)-4-bromo-2-(((dimethylamino)methylene)amino)benzoate 
• 158580-57-5 methyl 4-bromo-2-nitrobenzoate 
• 832114-32-6 7-Bromo-1-(4-methoxy-benzyl)-1H-quinazolin-4-one 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 68-12-2 N,N-dimethyl-formamide 
• 67-56-1 methanol 
• 112253-70-0 2-amino-4-bromobenzamide 
• 99277-71-1 4-bromo-2-nitrobenzoic acid 
• 194851-17-7 7-bromo-4-(3-chloro-4-fluoroanilino)quinazoline hydrochloride salt 

Downstream Products

• 573675-55-5 7-bromo-4-chloro-quinazoline 
• 1420990-58-4 C₂₁H₁₆F₂N₆O₂S 
• 1420990-50-6 3-benzyl-7-bromo-6-nitroquinazolin-4(3H)-one 
• 1420990-51-7 6-amino-3-benzyl-7-bromoquinazolin-4(3H)-one 
• 1420990-52-8 3-benzyl-7-bromo-6-[(4-chloro-5H-1,2,3-dithiazol-5-ylidene)amino]quinazolin-4(3H)-one 

Relevant articles and documents

Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3

Erythropoietin-producing human hepatocellular carcinoma (Eph) receptor tyrosine kinases (RTKs) regulate a variety of dynamic cellular events, including cell protrusion, migration, proliferation, and cell-fate determination. Small-molecule inhibitors of Eph kinases are valuable tools for dissecting the physiological and pathological roles of Eph. However, there is a lack of small-molecule inhibitors that are selective for individual Eph isoforms due to the high homology within the family. Herein, we report the development of the first potent and specific inhibitors of a single Eph isoform, EphB3. Through structural bioinformatic analysis, we identified a cysteine in the hinge region of the EphB3 kinase domain, a feature that is not shared with any other human kinases. We synthesized and characterized a series of electrophilic quinazolines to target this unique, reactive feature in EphB3. Some of the electrophilic quinazolines selectively and potently inhibited EphB3 both in vitro and in cells. Cocrystal structures of EphB3 in complex with two quinazolines confirmed the covalent linkage between the protein and the inhibitors. A "clickable" version of an optimized inhibitor was created and employed to verify specific target engagement in the whole proteome and to probe the extent and kinetics of target engagement of existing EphB3 inhibitors. Furthermore, we demonstrate that the autophosphorylation of EphB3 within the juxtamembrane region occurs in trans using a specific inhibitor. These exquisitely specific inhibitors will facilitate the dissection of EphB3's role in various biological processes and disease contribution.

Electrosynthesis of CF3-Substituted Polycyclic Quinazolinones via Cascade Trifluoromethylation/Cyclization of Unactivated Alkene

An atom and step economy cascade trifluoromethylation/cyclization of unactivated alkene with Langlois reagent as a CF3 source is described. A variety of polycyclic quinazolinones were successfully synthesized in 52–81% yields under transition metal- and oxidant-free conditions. The Langlois reagent used in this strategy as a CF3 reagent possesses the advantages of bench-stablity, cost-effectivity and high-efficiency. Additionally, gram-scale reaction, broad substrate scope and good functional group tolerance demonstrated the synthetic usefulness of this protocol.

Visible-Light Photosynthesis of CHF2/CClF2/CBrF2-Substituted Ring-fused Quinazolinones in Dimethyl Carbonate

With eco-friendly and sustainable CO2-derived dimethyl carbonate as the sole solvent, the visible-light-induced cascade radical reactions have been established as a green and efficient tool for constructing various CHF2/CClF2/CBrF2-substituted ring-fused quinazolinones.